Stifel Nicolaus Keeps Their Buy Rating on Neurogene (NGNE)
Stifel Nicolaus analyst Paul Matteis maintained a Buy rating on Neurogene (NGNE – Research Report) today and set a price target of $46.00. The ...
Stifel Nicolaus Reaffirms Their Buy Rating on Disc Medicine (IRON)
In a report released today, Benjamin Burnett from Stifel Nicolaus maintained a Buy rating on Disc Medicine (IRON – Research Report), with a ...